|
Under the agreement, KINAXO will make its KinaTor(TM) technology available to Takeda researchers involved in drug discovery, preclinical research and clinical development
Martinsried, Germany, April 16, 2008 | KINAXO Biotechnologies announced today that it has entered an agreement with Takeda San Diego, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited Osaka, Japan. Under the agreement, KINAXO will make its KinaTor(TM) technology available to Takeda researchers involved in drug discovery, preclinical research and clinical development. KINAXO’s Cellular Target Profiling utilizes proprietary chemical proteomics technologies combined with state-of-the-art mass spectrometry to identify and characterize a drug candidate’s native molecular targets in cell lines and tissue samples. This service enables pharmaceutical and biotechnology companies to make more informed decisions on which drug candidates to progress into advanced pre-clinical or clinical development. “We consider this agreement with Takeda, the leading R&D-oriented pharmaceutical company of Japan, to be a major progress in the world-wide expansion of our business”, said Dr. Andreas Jenne, the chief executive officer of KINAXO. “We continue to demonstrate the validation of the KinaTor(TM) technology by providing services to leading pharmaceutical and biotechnology companies, including Johnson& Johnson, Bayer-Schering, Takeda and UCB Pharma.”
About KINAXO
KINAXO Biotechnologies is a privately-held biotechnology company based in Munich/Martinsried, Germany. We support pharmaceutical and biotechnology companies in their development and optimization of drug leads. Amongst others KINAXO has ongoing collaborations with UCB Pharma and Johnson & Johnson. KINAXO offers its clients a comprehensive chemical-proteomics platform - known as KinaTor(TM) - that identifies and characterizes the interaction of small molecule inhibitors with their cellular protein targets. Tailored to protein kinases, the KinaTor(TM) technology supports more informed lead candidate selection. Licensing agreements with GPC Biotech AG and the Max Planck Society provides KINAXO Biotechnologies GmbH with exclusive worldwide rights to use the KinaTor(TM) technology in contract research activities. KINAXO is financed by European investors BioM, High-Tech Gründerfonds, KfW, Max Planck Society, and Mountain Partners.
SOURCE: KINAXO Biotechnologies |
